Pacira Q3 revenue up 31% to $167.5M, GAAP net loss $0.7M; EXPAREL sales $132.6M, patent to 2041

Pacira BioSciences, Inc.

2022-Q3 EPS reported $0.56 revenue$494,868,000

Total revenues $167.5M (+31% YoY); EXPAREL $132.6M (+9%), ZILRETTA $26.5M.
GAAP net loss $0.7M ($0.02 loss/share) vs prior-year net income $17.7M ($0.40).
Non-GAAP net income $29.9M ($0.65/share); adjusted EBITDA $55.2M vs $48.1M.
New EXPAREL composition patent (No. 11,452,691) expires Jan 2041; positive Phase 3 lower extremity nerve block results.
CHMP positive opinion for pediatric EXPAREL use; encouraging Phase 1 data for PCRX-201 gene therapy.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Pacira BioSciences, Inc. reported the third quarter ended September 30, 2022 results: revenue $167.5 million, net income $0.7 million, or $(0.02) per share (basic and diluted), EPS $(0.02) per share (basic and diluted).

Period: the third quarter ended September 30, 2022
Revenue: $167.5 million
Net income: $0.7 million, or $(0.02) per share (basic and diluted)
EPS: $(0.02) per share (basic and diluted)
Result: reported results

Exact text from the filing

in such a filing. --- EX-99.1 (EX-99.1) --- FOR IMMEDIATE RELEASE NEWS RELEASE Pacira BioSciences Reports Third Quarter 2022 Financial Results -- Third quarter revenue of $167 million, increased 31% over prior year -- -- Conference call today at 8:30 a.m. ET -- TAMPA, FL, November 3, 2022 - Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its

View on SEC.gov

Browse all earnings releases →

Pacira BioSciences, Inc. filing history →

Source: SEC EDGAR

accession 0001396814-22-000066

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.